Collaborations & Alliances
Related Searches:
Filter by:
721 - 735 of 1104 results
July 10, 2009
Addex Pharmaceuticals reached the second preclinical milestone in an exclusive collaboration and license agreement with Merck, focused on developing allosteric modulators for treatment of Parkinson's disease and other undisclosed indications.
Read More »
July 9, 2009
Merck and Portola Pharmaceuticals, Inc. have signed an exclusive global collaboration and license agreement for the development and commercialization of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II developmen
Read More »
July 8, 2009
AstraZeneca plans to further develop AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and will make a $10 million milestone payment to Targacept.
Read More »
July 7, 2009
Norwich Pharmaceuticals, Inc. has formed a strategic alliance with Emerson Resources, Inc. focused on bringing together the capabilities of the two companies in order to provide a broader range of services to the industry.
Read More »
July 7, 2009
Galapagos NV has successfully identified a second preclinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK) and reached a milestone on another compound, triggering payments to Galapagos totaling $7.3 million.
Read More »
July 6, 2009
Novartis has committed to a 10-year term of the strategic alliance with MorphoSys
Read More »
July 1, 2009
Astellas Pharma and Maxygen will establish a joint venture focused on the discovery, research and development of multiple protein pharmaceutical programs, including Maxygen’s MAXY-4 program and other early stage programs.
Read More »
June 30, 2009
Wyeth and Catalyst Biosciences, Inc. have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions.
Read More »
June 29, 2009
MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.
Read More »
June 29, 2009
Mylan Inc. and Biocon Ltd. have entered a definitive agreement to collaborate on the development, manufacture, supply and commercialization of multiple, generic biologic compounds.
Read More »
June 24, 2009
GlaxoSmithKline and Chroma Therapeutics have formed a collaboration to develop macrophage-targeted compounds
Read More »
June 18, 2009
Eden Biodesign Ltd. and Selexis have expended their collaboration via a joint marketing partnership, which will provide global biopharma companies access to their services for the development of monoclonal antibodies and recombinant proteins derived from
Read More »
June 16, 2009
MorphoSys AG and Schering-Plough have extended their antibody collaboration for another year.
Read More »
June 15, 2009
GSK returns rights to chemotherapy treatment elesclomol to Synta Pharma
Read More »
June 11, 2009
Xenon has entered into a strategic alliance with Merck to discover and develop small molecule candidates for the potential treatment of cardiovascular disease.
Read More »
721 - 735 of 1104 results
